# OnCo record paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021" ;
  schema:name "KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma"@en ;
  schema:description "In a head-to-head trial, the PD-1 antibody pembrolizumab kept relapsed Hodgkin lymphoma at bay for longer than brentuximab vedotin, making immunotherapy the preferred choice after transplant failure or for patients who cannot have a transplant."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00005-X>, <https://pubmed.ncbi.nlm.nih.gov/33721562/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(21)00005-X> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Kuruvilla J, Ramchandren R, Santoro A, et al." ;
  onco:cancers <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:trials <https://onco.cc/trials/keynote-204/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .